We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

CDK

CDK inhibitors block cyclin-dependent kinases (CDKs), the serine/threonine kinases that drive the cell cycle. Each CDK becomes active only when bound to a cyclin partner, and successive cyclin-CDK complexes order DNA replication and mitosis. CDK4 and CDK6 pair with D-type cyclins to control progression through G1, while CDK1 governs entry into mitosis. Palbociclib and abemaciclib are selective CDK4/6 inhibitors used to study G1 arrest and retinoblastoma protein phosphorylation. Dinaciclib and seliciclib act on several family members, including CDK2, CDK5 and CDK9, which also links them to transcription research. Ro 3306 inhibits CDK1 and is used to hold cells reversibly at the G2/M boundary for synchronization experiments.

4 Items

  • DCB-3503
    Cat. No.
    A37601
    CAS No.
    87302-58-7

    DCB-3503

    DCB-3503 is an allosteric modulator targeting heat shock cognate protein HSC70, functioning as an inhibitor of Cyclin D1. By allosterically modulating the ATPase and chaperone activities of HSC70, DCB-3503 effectively inhibits the translation of Cyclin D1. This compound holds potential for research applications focused on malignancies characterized by elevated Cyclin D1 expression, such as hepatocellular carcinoma and breast cancer.

    In stock View Details
    25 mg
    $1,655.00
    50 mg
    $2,115.00
    All 3 sizes
  • [pThr3]-CDK5 Substrate
    Cat. No.
    A54326
    CAS No.
    1670273-47-8

    [pThr3]-CDK5 Substrate

    [pThr3]-CDK5 Substrate is a specific substrate for cyclin-dependent kinase 5 (CDK5), functioning primarily through phosphorylation at threonine 3. This substrate is based on the histone H1 peptide sequence, which effectively binds within the active site of CDK5. It is phosphorylated by CDK5 with a Km value of 6 µM, making it useful for studies examining CDK5 activity and regulation in various biological contexts.

    View Details

    Out of stock

    All 3 sizes
  • Anticancer agent 300
    Cat. No.
    A54466
    CAS No.
    1310059-06-3

    Anticancer agent 300

    Anticancer Agent 300 (compound P14) is a modulator of CCND1, CDK4, CDK6, and CCNE1, exhibiting significant anti-proliferative properties. This compound influences cell cycle regulation, induces senescence, and promotes apoptosis in cancer cells. It is applicable in research related to ER+/HER2− breast cancer and BRAF-mutant melanoma, providing valuable insights for cancer therapeutics.

    View Details

    Out of stock

    All 3 sizes
  • CDK9 ligand 4
    Cat. No.
    A81329
    CAS No.
    2609749-29-1

    CDK9 ligand 4

    CDK9 ligand 4 functions as a potent ligand for cyclin-dependent kinase 9 (CDK9). This compound is instrumental in the design and development of PROTAC-based degraders, facilitating targeted degradation of CDK9 proteins, which plays a crucial role in transcriptional regulation and HIV-1 infection research. CDK9 ligand 4 contributes significantly to studies aimed at therapeutic strategies against viral infections and dysregulated transcriptional processes.

    View Details

    Out of stock

    All 3 sizes

4 Items

Added to your cart

View Cart Checkout

    Loading...